Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CALC Stock Forecast 2025-2026
$1.71
Current Price
$24.45M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CALC Price Targets
+1,069.6%
To High Target of $20.00
+806.4%
To Median Target of $15.50
+660.2%
To Low Target of $13.00
CALC Price Momentum
-14.5%
1 Week Change
+11.8%
1 Month Change
-66.9%
1 Year Change
-51.7%
Year-to-Date Change
-71.6%
From 52W High of $6.02
+19.6%
From 52W Low of $1.43
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching Calcimedica (CALC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on CALC and similar high-potential opportunities.
Latest CALC Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, CALC has a bullish consensus with a median price target of $15.50 (ranging from $13.00 to $20.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $1.71, the median forecast implies a 806.4% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Pantginis at HC Wainwright & Co., projecting a 1,069.6% upside. Conversely, the most conservative target is provided by Dev Prasad at LUCID CAPITAL MARKETS, suggesting a 660.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CALC Analyst Ratings
4
Buy
0
Hold
0
Sell
CALC Price Target Range
Low
$13.00
Average
$15.50
High
$20.00
Current: $1.71
Latest CALC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CALC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Apr 1, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Dec 17, 2024 | LUCID CAPITAL MARKETS | Dev Prasad | Buy | Initiates | $13.00 |
| Nov 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $16.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $16.00 |
| Aug 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Jul 10, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $20.00 |
| Jul 9, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Jun 27, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| May 14, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Swayampakula Ramakanth | Buy | Reiterates | $20.00 |
| Apr 1, 2024 | Oppenheimer | Leland Gershell | Outperform | Maintains | $14.00 |
| Mar 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Feb 16, 2024 | JonesTrading | Catherine Novack | Buy | Initiates | $22.00 |
| Feb 13, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Jan 29, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Initiates | $20.00 |
| Nov 13, 2023 | Oppenheimer | Leland Gershell | Outperform | Reiterates | $14.00 |
| Jul 7, 2023 | EF Hutton | Buy | Reiterates | $0.00 | |
| Jun 20, 2023 | EF Hutton | Buy | Initiates | $0.00 |
Calcimedica Inc. (CALC) Competitors
The following stocks are similar to Calcimedica based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Calcimedica Inc. (CALC) Financial Data
Calcimedica Inc. has a market capitalization of $24.45M with a P/E ratio of 0.3x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -134.2%.
Valuation Metrics
Market Cap
$24.45M
Enterprise Value
$9.96M
P/E Ratio
0.3x
PEG Ratio
-1.1x
Price/Sales
0.0x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+103.0%
Current Ratio
5.7x
Debt/Equity
79.0x
ROE
-134.2%
ROA
-59.4%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Calcimedica Inc. (CALC) Business Model
About Calcimedica Inc.
What They Do
Develops therapies targeting calcium channels.
Business Model
Calcimedica Inc. generates revenue by developing innovative biopharmaceutical therapies aimed at treating inflammatory diseases through targeted CRAC channel inhibitors. The company focuses on research and development to create effective treatments for conditions like acute pancreatitis and acute lung injuries, leveraging its specialized expertise in biotechnology and healthcare.
Additional Information
The company is positioned at the forefront of advancing targeted molecular therapies, which are vital for managing severe inflammatory conditions. Its work not only contributes to the biotech sector but also addresses significant unmet medical needs, enhancing its potential impact and attractiveness to investors.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
CEO
Dr. A. Rachel Leheny Ph.D.
Country
United States
IPO Year
2023
Website
calcimedica.comCalcimedica Inc. (CALC) Latest News & Analysis
Latest News
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
9 days ago
Quick Summary
CalciMedica's Phase 2 KOURAGE trial for Auxoraâ„¢ in AKI and respiratory failure is ongoing, with results expected late 2025. The company has sufficient cash to fund operations into mid-2026.
Why It Matters
CalciMedica's ongoing trials for Auxora in AKI and COVID-19 show promising mortality reduction data, potentially boosting its market value and investor interest as results approach.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CalciMedica (Nasdaq: CALC) will present a poster at Digestive Disease Week 2025 in San Diego, focusing on CRAC channel inhibition therapies for inflammatory and immunologic conditions.
Why It Matters
CalciMedica’s participation in a major conference highlights its ongoing development in innovative therapies, potentially attracting investor interest and impacting stock performance based on future results.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CalciMedica Inc. (CALC) has received a Zacks Rank #2 (Buy) upgrade, indicating increased optimism about its earnings prospects, which may boost the stock price short-term.
Why It Matters
CalciMedica's upgrade to a Zacks Rank #2 indicates increased confidence in its earnings potential, likely leading to a stock price rise and attracting more investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
CalciMedica Inc. (Nasdaq: CALC) has announced the appointment of Rachel Leheny, Ph.D. as part of its focus on CRAC channel inhibition therapies for inflammatory and immunologic diseases.
Why It Matters
CalciMedica's focus on CRAC channel therapies highlights potential advancements in treating inflammatory diseases, impacting future revenue and stock performance for investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CalciMedica's Phase 2 KOURAGE trial for Auxora in AKI and respiratory failure is ongoing, with data expected by late 2025. A post-hoc analysis indicated a 62.7% reduction in mortality for AKI patients. Cash reserves should support operations until mid-2026.
Why It Matters
Positive trial results and ongoing enrollment in significant studies may signal potential market success for CalciMedica's Auxora, influencing investor confidence and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
CalciMedica reported a 62.7% reduction in 30-day mortality for patients with AKI treated with Auxora compared to placebo. Results persisted through day 60, indicating ongoing efficacy.
Why It Matters
A significant reduction in mortality for patients treated with Auxora signals potential market value and efficacy, influencing CalciMedica’s stock performance and investor confidence in its pipeline.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About CALC Stock
What is Calcimedica Inc.'s (CALC) stock forecast for 2025?
Based on our analysis of 6 Wall Street analysts, Calcimedica Inc. (CALC) has a median price target of $15.50. The highest price target is $20.00 and the lowest is $13.00.
Is CALC stock a good investment in 2025?
According to current analyst ratings, CALC has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CALC stock?
Wall Street analysts predict CALC stock could reach $15.50 in the next 12 months. This represents a 806.4% increase from the current price of $1.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Calcimedica Inc.'s business model?
Calcimedica Inc. generates revenue by developing innovative biopharmaceutical therapies aimed at treating inflammatory diseases through targeted CRAC channel inhibitors. The company focuses on research and development to create effective treatments for conditions like acute pancreatitis and acute lung injuries, leveraging its specialized expertise in biotechnology and healthcare.
What is the highest forecasted price for CALC Calcimedica Inc.?
The highest price target for CALC is $20.00 from Joseph Pantginis at HC Wainwright & Co., which represents a 1,069.6% increase from the current price of $1.71.
What is the lowest forecasted price for CALC Calcimedica Inc.?
The lowest price target for CALC is $13.00 from Dev Prasad at LUCID CAPITAL MARKETS, which represents a 660.2% increase from the current price of $1.71.
What is the overall CALC consensus from analysts for Calcimedica Inc.?
The overall analyst consensus for CALC is bullish. Out of 6 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.50.
How accurate are CALC stock price projections?
Stock price projections, including those for Calcimedica Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 2:27 AM UTC